Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07503613 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy

StatusEnrolling by Invitation
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Secondary endpoints: 1 to 4v3
  2. Start date changed from estimate of Mar 2026 to Mar 2, 2026
    • Study description revised
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This multi-center, observational, post-intervention LTFU study will monitor for safety and efficacy of AAVAnc80- antiVEGF in individuals with vestibular schwannoma who have previously received an intracochlear administration of AAVAnc80-antiVEGF in an interventional clinical trial
Trial Details
NCT Number NCT07503613
Lead Sponsor Akouos, Inc.
Collaborators: Eli Lilly and Company
Conditions
(from sponsor)		 Vestibular Schwannoma
Related terms Hearing Loss, Neuroma, Acoustic
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov